The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
暂无分享,去创建一个
C. Held | B. Lewis | R. Diaz | M. Nieminen | M. Pfisterer | P. Armstrong | H. White | K. Mahaffey | H. Tan | D. Morrow | J. Jukema | L. Wallentin | A. Lincoff | C. Bode | M. Valgimigli | J. Cornel | K. Huber | R. Harrington | D. Whellan | P. Aylward | F. Werf | G. Montalescot | D. Moliterno | G. Ambrosio | Á. Cequier | J. Nicolau | J. Nordrehaug | H. Ogawa | R. Storey | P. Tricoci | A. Betriu | P. Widimsky | W. Rużyłło | P. Grande | P. Ofner | L. Providência | Ming-Fong Chen | M. Hudson | E. Veltri | T. Timurkaynak | J. Prieto | J. Strony | A. Dalby | Chen Ming-Fong | L. Wong | E. Chen | Park Seung-Jung | D. Isaza | J. Yamaguchi
[1] R. Califf,et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.
[2] Marc P. Bonaca,et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. , 2009, American heart journal.
[3] K. Mahaffey,et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study , 2009, The Lancet.
[4] Angelo Branzi,et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. , 2007, European heart journal.
[5] William Wijns,et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[6] J. Alpert,et al. Universal definition of myocardial infarction. , 2007, European heart journal.
[7] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[8] J. Ornato,et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.
[9] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[10] A. Leger,et al. Protease-Activated Receptors in Cardiovascular Diseases , 2006, Circulation.
[11] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[12] Patrice Cacoub,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.
[13] Deepak L. Bhatt,et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. , 2006, Archives of internal medicine.
[14] A. Kastrati,et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.
[15] Robert M Califf,et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.
[16] R. Califf,et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. , 2005, JAMA.
[17] R. Califf,et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.
[18] A. Skene,et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.
[19] Nicola J Cooper,et al. A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. , 2005, Journal of clinical epidemiology.
[20] Sunil V. Rao,et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.
[21] F. Fauvel-Lafève,et al. Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] R. Califf,et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.
[23] A. Laupacis,et al. Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies , 2004 .
[24] M. Takano,et al. Elevated Troponin T Levels and Lesion Characteristics in Non–ST-Elevation Acute Coronary Syndromes , 2004, Circulation.
[25] R. Califf,et al. Inhibition of Platelet Aggregation with a Glycoprotein IIb-IIIa Antagonist Does Not Prevent Thrombin Generation in Patients Undergoing Thrombolysis for Acute Myocardial Infarction , 2004, Journal of Thrombosis and Thrombolysis.
[26] J. Seki,et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. , 2003, European journal of pharmacology.
[27] M. D'Andrea,et al. Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates , 2003, Journal of Pharmacology and Experimental Therapeutics.
[28] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[29] S. Yusuf,et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. , 2002, European heart journal.
[30] K. Eagle,et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). , 2002, The American journal of cardiology.
[31] M. Anderluh,et al. Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. , 2002, Current medicinal chemistry.
[32] S. Goto,et al. Functional Significance of Adenosine 5′-Diphosphate Receptor (P2Y12) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ib&agr; Induced by Conditions of High Shear Rate , 2002, Circulation.
[33] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[34] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[35] K Fujikawa,et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[36] D. Doller,et al. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. , 1999, Bioorganic & medicinal chemistry letters.
[37] R. Davies,et al. A Highly Efficient Total Synthesis of (+)-Himbacine , 1996 .
[38] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.